Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema; the main goals of treatment are to protect the skin barrier, reduce inflammation, and alleviate itch. Topical therapies (e.g., corticosteroids) are often effective for mild disease but suffer from suboptimal safety, tolerability, and compliance. More-effective therapies for topical-refractory patients and, more generally, those with moderate to severe AD are also sorely needed and are a key focus of the burgeoning AD pipeline. Pfizer’s nonsteroidal topical Eucrisa (crisaborole) and Sanofi / Regeneron’s injectable biologic Dupixent (dupilumab) are the first in a series of new entrants we expect to transform the AD treatment algorithm. This report provides a comprehensive analysis of AD patient populations, current disease management, lingering unmet needs, and the clinical and commercial potential of emerging drugs.

QUESTIONS ANSWERED

  • How large are the mild, moderate, and severe AD subpopulations, and how will they change by 2027? How well are these populations served by current AD therapies?
  • How have the launches of Pfizer’s Eucrisa and Sanofi / Regeneron’s Dupixent altered the AD treatment landscape?
  • What emerging therapies are in development for AD? Of these therapies, which are best poised to achieve commercial success?
  • What are the greatest unmet needs, and to what degree will emerging therapies in the pipeline address these needs?

PRODUCT DESCRIPTION

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • COVID-19
    • Key Findings
      • Atopic Dermatitis - Key Findings - December 2019
    • Market Outlook
      • Key Findings
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Atopic Dermatitis?
        • What Factors Are Constraining the Market for Atopic Dermatitis?
      • Drug-Class-Specific Trends
        • IL-4/IL-13 Inhibitors
        • IL-31 Inhibitors
        • Neurokinin-1 Receptor Antagonists
        • Oral JAK Inhibitors
        • Topical JAK Inhibitors
        • Topical Calcineurin Inhibitors
        • Topical Phosphodiesterase-4 Inhibitors
        • JAK Inhibitors
    • Forecast
    • Etiology and Pathophysiology
      • Disease Overview
      • Clinical Presentation
      • Atopic Dermatitis Risk and Protective Factors
      • Social and Economic Burden of Atopic Dermatitis
      • Cutaneous Immunity
      • The Skin Barrier
      • Skin Barrier Defects
      • Altered Immune Reactivity and the Skin Microbiome
      • Key Pathways and Drug Targets
    • Epidemiology Overview
      • Key Findings
        • Key Updates
      • Epidemiology Populations
        • 12-Month Total Prevalent Cases of Atopic Dermatitis
        • Severity of 12-Month Total Prevalent Cases of Atopic Dermatitis
        • Diagnosed Prevalent Cases of Atopic Dermatitis
        • Severity of Diagnosed 12-Month Prevalent Cases of Atopic Dermatitis
        • Diagnosed Drug-Treated 12-Month Prevalent Cases By Severity
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Topical Phosphodiesterase-4 Inhibitors
        • IL-4/IL-13 Inhibitors
        • Topical Calcineurin Inhibitors
        • Topical Corticosteroids
        • Conventional Oral Immunosuppressants
        • Emollients
        • Phototherapy
        • Other Therapies Used in the Treatment of Atopic Dermatitis
      • Medical Practice
        • Overview
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Atopic Dermatitis
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • IL-13 Inhibitors
        • IL-31 Inhibitors
        • IL-33 Inhibitors
        • Neurokinin-1 Receptor Antagonists
        • Oral JAK Inhibitors
        • Topical JAK Inhibitors
        • Histamine H4 Receptor Antagonists
        • Topical Phosphodiesterase-4 Inhibitors
        • Anti-Inflammatory Fatty Acids
        • Aryl Hydrocarbon Receptor Agonists
      • Early-Phase Pipeline Analysis
      • Key Discontinuations and Failures in Atopic Dermatitis
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Atopic Dermatitis Bibliography

Author(s): Ian Love, PhD; Kurt White

Ian is an analyst on the Infectious, Niche, and Rare Diseases team at Decision Resources Group, specializing in niche and rare diseases. Ian conducts primary and secondary research to gauge the market landscapes of these diseases, thoroughly analyzing disease etiology, current treatments, unmet need, and emerging therapies expected to impact their respective markets. He received his doctorate in biomedical sciences from the University of Massachusetts Medical School and his in cell & molecular biology from the Worcester Polytechnic Institute. Prior to joining Decision Resources Group, Dr. Love was an Instructor in the Department of Internal Medicine at Virginia Commonwealth University.

Kurt is an associate epidemiologist and joined Decision Resources Group in ; He has significant experience with statistical methods such as multivariate linear regression and logistic regression.  He completed his master’s and doctoral degree (MPH, PhD) in Epidemiology at Indiana University School of Public Health, where he worked on projects investigating the relationship between physical activity and infectious disease health ; He also completed his master’s (MA) in anthropology at Indiana University and his master’s (MS) in biology at Indiana University-Purdue University ;